YN320741 JNJ-7777120 459168-41-3

JNJ-7777120 is the first potent and selective non-imidazole histamine H4 receptor antagonist with Ki of 4.5 nM, exhibits >1000-fold selectivity over the other histamin receptors.

YN250383 Sordarin sodium 463356-00-5

Sordarin is a potent diphthamide-dependenteEF2inhibitor withantifungalproperties. Sordarin targets eEF2 so as to inhibit protein translation by blocking eEF2-mediated translocation of tRNAs. Sordarin inhibits translation specifi...

YN320942 SSR240612 464930-42-5

SSR240612 is a potent, and orally active specific non-peptidebradykinin B1 receptorantagonist, with Kis of 0.48nM and 0.73nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 4...

YN320384 Plecanatide 467426-54-6

Plecanatide, an analogue of Uroguanylin, is an orally activeguanylate cyclase-C (GC-C) receptoragonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190nM in T84 cells assay. Plecanatide...

YN320962 AMG 487 473719-41-4

AMG 487 is an orally active and selective CXC chemokine receptor 3 (CXCR3) antagonist that inhibits the binding of IP-10 (CXCL10) and ITAC (CXCL11) to CXCR3 with IC50 of 8.0 nM and 8.2 nM, respectively...

YN320210 Navarixin 473727-83-2

SCH-527123 is a potent, orally bioavailable CXCR2/CXCR1 antagonist with IC50 values of 2.6 nM and 36 nM, respectively.

YN320003 SCH 563705 473728-58-4

SCH 563705 is a potent and orally availableCXCR2 and CXCR1antagonist, with IC50s of 1.3nM, 7.3nM and Kis of 1 and 3nM, respectively.

YN330186 SM-276001 473930-22-2

SM-276001 is a potent selectiveTLR7agonist that can induce antitumor immune responses. SM-276001 is an orally activeinterferon(IFN) inducer.

YN320306 SB-657510 474960-44-6

SB-657510 is a selectiveurotensin II (UII) receptor (UT)antagonist. TheKivalues are 61, 17, 30, 65 and 56nM for human, monkey, cat, rat and mouse receptors, respectively. SB-657510 exerts anti-inflammatory effects by inhib...

YN360551 A-317491 475205-49-3

A-317491 is a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors with Ki values of 22 nM and 9 nM for human P2X3 and P2X2/3 receptors.

YN483854 NEP(1-40) 475221-20-6

NEP(1-40) is aNogo-66 receptor (NgR)antagonist peptide, reversing the injury-induced shift in distribution of microglia morphologies by limiting myelin-based inhibition.

YN330018 CORM-3 475473-26-8

CORM-3, a carbon monoxide-releasing molecule, attenuates NF-κB p65nuclear translocation, reduces ROS generation and enhances intracellular glutathione and superoxide dismutase levels. CORM-3 reduces NLRP3 inflammasome...

YN484107 LKKTETQ 476014-70-7

LKKTETQ, a peptide segment, is the active site within the protein thymosin β4responsible for actin binding, cell migration and wound healing.

YN340232 Tofacitinib 477600-75-2

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1.

YN481552 ISO-1 478336-92-4

ISO-1 is an inhibitor of MIF (Macrophage migration inhibitory factor) D-dopachrome tautomerase activity with an IC50 of ~7 μM.

YN370422 AUDA 479413-70-2

AUDA (compound 43) is a potent inhibitor of soluble epoxide hydrolase (sEH) with IC50 of 18 nM and 69 nM for the mouse sEH and human sEH, respectively. AUDA has anti-inflammatory activity that reduces the protein expressio...

YN480093 CD80-IN-3 486449-65-4

CD80-IN-3, a potent CD80 inhibitor, inhibits CD80/CD28 interaction with an EC50 of 630nM and aKdof 125nM.

YN320014 DW-1350 491577-61-8

DW-1350 is a LTB4receptorantagonist.

YN340276 Ginsenoside Rk1 494753-69-4

Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3signaling pathway ...

YN320754 Beraprost sodium 496807-11-5

Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug ofPGI2. Beraprost sodium is a potentvasodilator, has the potential for pulmonary arterial hypertension treatment through exp and ing renal vessels, improv...